[1]韩斌,李川,葛楠,等.ⅢA期非小细胞肺癌术前靶向治疗对手术效果影响[J].齐鲁医学杂志,2017,32(03):274-275.[doi:10.13362/j.qlyx.201703007]
 HAN Bin,LI Chuan,GE Nan,et al.CLINICAL EFFECT OF PREOPERATIVE TARGETED THERAPY ON SURGICAL OUTCOME OF STAGE ⅢA NON-SMALL CELL LUNG CANCER[J].Medical Journal of Qilu,2017,32(03):274-275.[doi:10.13362/j.qlyx.201703007]
点击复制

ⅢA期非小细胞肺癌术前靶向治疗对手术效果影响()
分享到:

《齐鲁医学杂志》[ISSN:1008-0341/CN:37-1280/R]

卷:
第32卷
期数:
2017年03期
页码:
274-275
栏目:
出版日期:
2017-08-07

文章信息/Info

Title:
CLINICAL EFFECT OF PREOPERATIVE TARGETED THERAPY ON SURGICAL OUTCOME OF STAGE ⅢA NON-SMALL CELL LUNG CANCER
文章编号:
1008-0341(2017)03-0274-02
作者:
韩斌李川葛楠赵艳东沈毅矫文捷
青岛大学附属医院胸外科,山东 青岛 266003
Author(s):
HAN Bin LI Chuan GE Nan ZHAO Yandong SHEN Yi JIAO Wenjie
Department of Thoracic Surgery, The Affiliated Hospital of Qingdao University, Qingdao 266003, China
关键词:
受体表皮生长因子非小细胞肺分子靶向治疗外科手术治疗结果
Keywords:
receptor epidermal growth factor carcinoma non-small-cell lung molecular targeted therapy surgical procedures operative treatment outcome
分类号:
R730.26
DOI:
10.13362/j.qlyx.201703007
文献标志码:
A
摘要:
目的 探讨ⅢA期非小细胞肺癌术前靶向治疗对手术效果的影响。
方法 ⅢA期非小细胞肺癌病人6例,术前病理学检查确诊为腺癌,表皮生长因子受体(EGFR)基因检测19或21位点突变,口服靶向治疗药物EGFR络氨酸激酶抑制剂(EGFR-TKI)治疗,疗程4~16周。再次病情评估,肿瘤降期,6例病人行肺癌根治性切除(肺叶切除+淋巴结清扫)术,其中胸腔镜下手术5例,胸腔镜辅助开胸手术1例。
结果 6例病人手术时间180~260 min,平均(191±69)min;术中失血量50~100 mL,平均(63±35)mL。术后住院时间5~9 d,平均(6.3±2.1)d,均好转出院。手术标本病理学检查均证实为原发性肺腺癌(ⅢA期),癌组织纤维化较重,间质纤维化。
结论 ⅢA期非小细胞肺癌术前靶向治疗效果较好。
Abstract:
Objective  To investigate the clinical effect of preoperative targeted therapy on the surgical outcome of stage-ⅢA non-small cell lung cancer (NSCLC).
Methods  A total of six patients with stage ⅢA NSCLC were enrolled. Preoperative pathological examination showed adenocarcinoma, and the detection of epidermal growth factor receptor (EGFR) gene identified mutation at site 19 or 21. All the patients were given oral EGFR tyrosine kinase inhibitor as the targeted therapy, and the course of treatment was 4-16 weeks. The patients’ conditions and tumor downstaging were evaluated, and all patients underwent radical resection (pulmonary lobectomy+lymph node dissection), among whom five underwent thoracoscopic surgery and one underwent video-assisted thoracotomy.
Results  The time of operation was 180-260 minutes (mean (191±69) min), the intraoperative blood loss was 50-100 mL (mean (63±35) mL), and the length of postoperative hospital stay was 5-9 d (mean (6.3±2.1) d). All patients were improved and discharged. Pathological examination of the surgical specimens confirmed the diagnosis of primary lung adenocarcinoma (stage ⅢA) with extensive fibrosis of tumor tissue and interstitial fibrosis.
Conclusion  Preoperative targeted therapy for stage ⅢA NSCLC has a good clinical effect.
更新日期/Last Update: 2017-08-12